Promethera Biosciences, a Belgium-based liver disease therapy spinout from Université Catholique de Louvain, secured €9.3m ($11.5m) in convertible bond financing on Tuesday from investors including packaging system manufacturer Shibuya Corporation.
Shinsei Corporate Investment, the corporate venturing arm of financial services firm Shinsei Bank, also participated in the issue, as did unnamed existing investors.
Founded in 2009, Promethera Biosciences develops cell-based therapies for liver diseases. Its lead asset, HepaStem, has entered phase 2 clinical trials for acute-on-chronic liver failure and non-alcoholic…
